Peer-reviewed studies, clinical trials, and breakthrough discoveries shaping the future of human longevity
After decades of remarkable results in animal models - reversing aging, extending lifespan by 30-50%, and restoring youthful function - the most promising interventions are finally entering human clinical trials. 2026 marks the beginning of a new era in longevity medicine.
Read Full Analysis →Longevity Escape Velocity - when science extends life faster than you age - may be closer than we think. Discover how artificial intelligence is compressing decades of research into years, and why experts believe we could reach LEV within our lifetimes.
Read Full Analysis →First-in-human trials show dasatinib + quercetin combination reduces senescent cell burden by 40% in elderly patients, improving physical function.
Altos Labs demonstrates partial cellular reprogramming using modified OSKM factors, resetting epigenetic age markers by 30 years in vitro.
Interim results from the Targeting Aging with Metformin trial suggest significant delays in age-related disease onset in non-diabetic adults.
Clinical comparison shows subcutaneous NAD+ delivery dramatically outperforms oral precursors for restoring cellular NAD+ levels in aging adults.
Long-term data reveals GLP-1/GIP dual agonists reduce cardiovascular events, inflammation markers, and all-cause mortality independent of weight changes.
Mitochondrial-derived peptide MOTS-c restores insulin sensitivity and exercise capacity in aged mice, with human trials now underway.
Novel telomerase activators demonstrate safe telomere lengthening in human trials, challenging previous concerns about oncogenic potential.
Two-year moderate caloric restriction trial demonstrates 2-3% slowing of biological aging pace measured by DunedinPACE epigenetic clock.
AI-powered protein structure prediction identifies 12 new senolytic drug candidates in 3 months - work that would have taken years traditionally.
Intermittent rapamycin dosing enhances vaccine response and reduces infections in adults over 65, with minimal side effects at low doses.
Recombinant GDF11 administration improves cardiac function and exercise capacity in elderly patients with heart failure.
Phase II trial shows single infusion of allogeneic MSCs improves walking speed, grip strength, and quality of life in frail elderly.
Randomized trial demonstrates spermidine improves memory performance in older adults through autophagy-dependent mechanisms.
DunedinPACE 2.0 measures the pace of biological aging with unprecedented accuracy, enabling intervention tracking in real-time.
Long-term study reveals low-intensity aerobic exercise superior to high-intensity intervals for preserving mitochondrial function after 50.
Novel NLRP3 inflammasome inhibitor significantly reduces age-associated inflammation without immunosuppression in Phase II trial.
Unique gut bacteria from superagers transferred to elderly recipients improves glucose metabolism and reduces inflammation markers.
AAV-delivered telomerase and follistatin combination therapy dramatically extends healthspan in aged mice, with human trials planned for 2026.